722 related articles for article (PubMed ID: 33325008)
81. Design of a novel long-acting dual GLP-1/GIP receptor agonist.
Dong Y; Zhang J; Xu H; Shen H; Lu Q; Feng J; Cai Z
Bioorg Med Chem; 2024 Feb; 100():117630. PubMed ID: 38330849
[TBL] [Abstract][Full Text] [Related]
82. [Gastrointestinal hormones: their increasing pharmacotherapeutic relevance in metabolic diseases].
Gallwitz B
Inn Med (Heidelb); 2023 Feb; 64(2):205-210. PubMed ID: 36598526
[TBL] [Abstract][Full Text] [Related]
83. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
84. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis.
Dutta D; Surana V; Singla R; Aggarwal S; Sharma M
Indian J Endocrinol Metab; 2021; 25(6):475-489. PubMed ID: 35355921
[TBL] [Abstract][Full Text] [Related]
85. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
Meng Z; Yang M; Wen H; Zhou S; Xiong C; Wang Y
Front Endocrinol (Lausanne); 2023; 14():1121387. PubMed ID: 37051199
[TBL] [Abstract][Full Text] [Related]
86. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
87. Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes.
Vázquez LA; Romera I; Rubio-de Santos M; Escalada J
Diabetes Ther; 2023 Nov; 14(11):1771-1784. PubMed ID: 37713104
[TBL] [Abstract][Full Text] [Related]
88. [The "other" incretin - the therapeutic rediscovery of the glucose-dependent insulinotropic polypeptide].
Winkler G; Kis JT; Schandl L
Orv Hetil; 2023 Feb; 164(6):210-218. PubMed ID: 36774634
[TBL] [Abstract][Full Text] [Related]
89. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
90. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
[TBL] [Abstract][Full Text] [Related]
91. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
de Mesquita YLL; Pera Calvi I; Reis Marques I; Almeida Cruz S; Padrao EMH; Carvalho PEP; da Silva CHA; Cardoso R; Moura FA; Rafalskiy VV
Int J Obes (Lond); 2023 Oct; 47(10):883-892. PubMed ID: 37460681
[TBL] [Abstract][Full Text] [Related]
92. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
93. Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.
Al-Horani RA; Chedid M
Endocr Metab Immune Disord Drug Targets; 2023; 23(8):1046-1050. PubMed ID: 36200219
[TBL] [Abstract][Full Text] [Related]
94. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
Valentine WJ; Hoog M; Mody R; Belger M; Pollock R
Diabetes Obes Metab; 2023 May; 25(5):1292-1300. PubMed ID: 36655340
[TBL] [Abstract][Full Text] [Related]
95. Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease.
Alicic RZ; Neumiller JJ
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202209
[TBL] [Abstract][Full Text] [Related]
96. Gut hormone co-agonists for the treatment of obesity: from bench to bedside.
Nogueiras R; Nauck MA; Tschöp MH
Nat Metab; 2023 Jun; 5(6):933-944. PubMed ID: 37308724
[TBL] [Abstract][Full Text] [Related]
97. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
98. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
99. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
Tan B; Pan XH; Chew HSJ; Goh RSJ; Lin C; Anand VV; Lee ECZ; Chan KE; Kong G; Ong CEY; Chung HC; Young DY; Chan MY; Khoo CM; Mehta A; Muthiah MD; Noureddin M; Ng CH; Chew NWS; Chin YH
Int J Obes (Lond); 2023 Aug; 47(8):677-685. PubMed ID: 37253796
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
